Jubilant Pharmova Limited (NSE:JUBLPHARMA)

Jubilant Pharmova Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	-	12,671	10,883	9,564	10,139	9,838
Short-Term Investments	-	-	-	-	-	53.53
Cash & Short-Term Investments	12,671	12,671	10,883	9,564	10,139	9,892
Cash Growth	16.38%	16.43%	13.79%	-5.67%	2.50%	43.48%
Accounts Receivable	-	11,740	10,043	10,134	10,508	9,914
Other Receivables	-	2,798	1,433	2,534	1,678	1,497
Receivables	-	14,557	11,487	12,676	12,197	11,426
Inventory	-	12,543	11,486	13,038	14,215	12,861
Prepaid Expenses	-	1,041	1,050	910	900	833.54
Other Current Assets	-	281	866	2,573	173	79.99
Total Current Assets	-	41,093	35,772	38,761	37,624	35,092
Property, Plant & Equipment	-	69,033	51,682	36,871	33,652	27,911
Long-Term Investments	-	614	435	422	2,564	2,386
Goodwill	-	28,261	25,410	24,639	24,286	22,428
Other Intangible Assets	-	12,766	10,967	10,433	9,510	9,263
Long-Term Deferred Tax Assets	-	2,571	2,574	2,327	2,275	1,613
Other Long-Term Assets	-	886	721	2,029	1,652	1,211
Total Assets	-	155,227	127,564	115,485	111,567	99,909

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	-	12,341	10,048	8,563	8,213	5,677
Accrued Expenses	-	5,345	3,947	3,293	2,786	3,091
Short-Term Debt	-	1,625	2,190	1,965	2,583	640
Current Portion of Long-Term Debt	-	853	676	505	414	3,994
Current Portion of Leases	-	670	556	521	534	521.93
Current Income Taxes Payable	-	201	184	370	624	345.06
Current Unearned Revenue	-	2,517	1,286	998	719	909.81
Other Current Liabilities	-	1,837	2,759	2,675	1,851	737.41
Total Current Liabilities	-	25,389	21,646	18,890	17,724	15,916
Long-Term Debt	-	29,717	21,503	31,671	31,104	24,642
Long-Term Leases	-	3,282	2,385	1,978	2,133	2,122
Long-Term Unearned Revenue	-	13,720	11,375	5,438	2,685	72.96
Pension & Post-Retirement Benefits	-	955	715	542	482	516.25
Long-Term Deferred Tax Liabilities	-	2,507	1,722	2,108	3,062	3,030
Other Long-Term Liabilities	-	8,701	5,832	647	459	445.45
Total Liabilities	-	84,271	65,178	61,274	57,649	46,745

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	-	158	158	158	159	159.28
Retained Earnings	-	56,075	53,018	45,397	45,368	46,860
Comprehensive Income & Other	-	14,695	9,373	8,784	8,466	6,166
Total Common Equity	70,928	70,928	62,549	54,339	53,993	53,186
Minority Interest	-	28	-163	-128	-75	-21.63
Shareholders' Equity	70,956	70,956	62,386	54,211	53,918	53,164
Total Liabilities & Equity	-	155,227	127,564	115,485	111,567	99,909

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	36,147	36,147	27,310	36,640	36,768	31,920
Net Cash (Debt)	-23,476	-23,476	-16,427	-27,076	-26,629	-22,028
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-147.82	-147.75	-103.40	-170.44	-167.32	-138.39
Filing Date Shares Outstanding	158.26	158.39	158.4	158.35	159.07	159.17
Total Common Shares Outstanding	158.26	158.39	158.4	158.35	159.07	159.17
Working Capital	-	15,704	14,126	19,871	19,900	19,176
Book Value Per Share	447.81	447.81	394.89	343.16	339.43	334.14
Tangible Book Value	29,901	29,901	26,172	19,267	20,197	21,495
Tangible Book Value Per Share	188.78	188.78	165.23	121.67	126.97	135.04
Land	-	1,354	380	444	440	447.86
Buildings	-	12,325	7,459	8,622	8,498	7,957
Machinery	-	43,389	31,360	32,484	29,213	26,009
Construction In Progress	-	29,615	27,147	12,523	7,733	2,918

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 11, 2026

Data Sources Report a data error